BioSpace counts oral Wegovy among five drug launches that beat expectations
Novo booked $355 million in the pill's first quarter at a $149 monthly self-pay start, while BMO data shows Lilly's Foundayo scripts gaining ground.
Recap by typeshit. Full story at BioSpace.